AUS
NZ
UK
CA
USA
IND
Highlights
- Invion (IVX) commences trials for its advanced cancer treatment, INV043.
- The trial explores non-invasive therapy for non-melanoma skin cancer.
- Pre-clinical research suggests potential benefits of INV043 in cancer treatment.
Invion (ASX:IVX), a clinical-stage life sciences company, has officially commenced patient dosing in its Phase I/II trial targeting non-melanoma skin cancer (NMSC). This trial will evaluate the safety and effectiveness of INV043, a novel photosensitiser developed for photodynamic therapy (PDT), a minimally invasive treatment approach for various cancers.
Focus on Novel Skin Cancer Treatment
The ongoing trial involves the application of INV043 as a topical solution and is being conducted at Veracity Clinical Research in Queensland. The trial will recruit at least 18 participants diagnosed with non-metastatic cutaneous squamous cell carcinoma (cSCC) and superficial basal cell carcinoma (sBCC).
INV043 has shown potential benefits in pre-clinical research, including fewer side effects and a reduction in scarring compared to traditional surgical treatments. This innovative approach aims to provide an alternative for patients seeking effective and less invasive solutions.
Building on Positive Research Foundations
Invion’s move into NMSC trials follows promising outcomes from its Phase II prostate cancer trial, which also utilized INV043. These encouraging results set the stage for exploring further applications of the compound, including a Phase II anogenital cancer trial. The company aims to enhance its research by possibly incorporating immune checkpoint inhibitors, leveraging insights from the Peter MacCallum Cancer Centre in Victoria.
Aiming for Better Cancer Outcomes
Pre-clinical studies conducted at the Hudson Institute of Medical Research in Victoria demonstrated INV043’s potential to regress tumors while minimizing pain and avoiding the permanent scarring associated with conventional surgeries. The study also highlighted its possible broader applications in treating other types of cancer.
Non-melanoma skin cancers make up the vast majority of skin cancer cases globally. With the market for treatment expected to grow significantly, the need for innovative and effective therapies like INV043 becomes evident.
Invion’s adaptive trial design allows for adjustments during the study, potentially boosting its efficiency. This approach could pave the way for INV043 to emerge as a groundbreaking therapy in the growing photodynamic therapy landscape.
Invion’s efforts to advance PDT and develop safer, more effective treatments highlight its commitment to improving cancer care while addressing the limitations of current treatment methods. With INV043 showing significant promise, this trial marks a critical step forward in cancer therapy innovation.
